Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 120

Study on Hydroxyurea and Valproic Acid or 6-Mercaptopurine with Valproic Acid for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Study on Hydroxyurea and Valproic Acid or 6-Mercaptopurine with Valproic Acid for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

Study Comparing Conventional Radiotherapy and PSMA-PET/CT Targeted Treatment with 18F-PSMA-1007 and Gozetotide for Prostate Cancer Recurrence After Surgery

Study Comparing Conventional Radiotherapy and PSMA-PET/CT Targeted Treatment with 18F-PSMA-1007 and Gozetotide for Prostate Cancer Recurrence After Surgery

Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Study on Hydrochlorothiazide and Tolvaptan for Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study on Hydrochlorothiazide and Tolvaptan for Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study on Cisplatin, Gemcitabine, and Paclitaxel Albumin-Bound for Patients with Resectable Biliary Tract Cancer at High Risk of Recurrence

Study on Cisplatin, Gemcitabine, and Paclitaxel Albumin-Bound for Patients with Resectable Biliary Tract Cancer at High Risk of Recurrence

Study on the Effectiveness and Safety of Cisplatin and Paclitaxel in Advanced Ovarian Cancer Patients After Surgery

Study on the Effectiveness and Safety of Cisplatin and Paclitaxel in Advanced Ovarian Cancer Patients After Surgery

Study on Preoperative Treatment for HER2-Negative Breast Cancer Using Pembrolizumab, Paclitaxel, and Carboplatin in Patients Not Responding to Initial Chemotherapy

Study on Preoperative Treatment for HER2-Negative Breast Cancer Using Pembrolizumab, Paclitaxel, and Carboplatin in Patients Not Responding to Initial Chemotherapy

Study of Tucatinib, Etoposide, and Trastuzumab for Patients with Metastatic HER2+ Breast Cancer After Progression or Capecitabine Toxicity

Study of Tucatinib, Etoposide, and Trastuzumab for Patients with Metastatic HER2+ Breast Cancer After Progression or Capecitabine Toxicity

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or Ubamatamab for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or Ubamatamab for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer